45,714 Shares in Kenvue Inc. (NYSE:KVUE) Bought by Wilmington Savings Fund Society FSB

Wilmington Savings Fund Society FSB acquired a new stake in shares of Kenvue Inc. (NYSE:KVUE) during the third quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund acquired 45,714 shares of the company’s stock, valued at approximately $1,057,000.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. Sanctuary Advisors LLC increased its position in shares of Kenvue by 166.3% during the 3rd quarter. Sanctuary Advisors LLC now owns 544,890 shares of the company’s stock valued at $13,121,000 after purchasing an additional 340,266 shares during the period. Boyar Asset Management Inc. raised its position in Kenvue by 7.2% in the third quarter. Boyar Asset Management Inc. now owns 29,171 shares of the company’s stock worth $675,000 after acquiring an additional 1,948 shares in the last quarter. Bard Financial Services Inc. lifted its holdings in Kenvue by 5.7% in the 3rd quarter. Bard Financial Services Inc. now owns 106,790 shares of the company’s stock valued at $2,470,000 after acquiring an additional 5,750 shares during the last quarter. Soltis Investment Advisors LLC lifted its holdings in Kenvue by 3.7% in the 3rd quarter. Soltis Investment Advisors LLC now owns 151,858 shares of the company’s stock valued at $3,512,000 after acquiring an additional 5,475 shares during the last quarter. Finally, TD Private Client Wealth LLC boosted its position in shares of Kenvue by 5.6% during the 3rd quarter. TD Private Client Wealth LLC now owns 129,127 shares of the company’s stock valued at $2,987,000 after purchasing an additional 6,901 shares in the last quarter. Institutional investors own 97.64% of the company’s stock.

Kenvue Stock Down 0.5 %

Shares of Kenvue stock opened at $22.21 on Friday. The company has a current ratio of 1.00, a quick ratio of 0.69 and a debt-to-equity ratio of 0.66. Kenvue Inc. has a 1 year low of $17.67 and a 1 year high of $24.46. The stock has a 50-day moving average price of $22.95 and a 200 day moving average price of $21.20. The company has a market cap of $42.58 billion, a P/E ratio of 40.38, a P/E/G ratio of 2.02 and a beta of 1.36.

Kenvue (NYSE:KVUE) last posted its quarterly earnings results on Thursday, November 7th. The company reported $0.28 EPS for the quarter, topping the consensus estimate of $0.27 by $0.01. Kenvue had a net margin of 6.88% and a return on equity of 21.43%. The business had revenue of $3.90 billion during the quarter, compared to analysts’ expectations of $3.92 billion. During the same period last year, the company posted $0.31 earnings per share. The firm’s quarterly revenue was down .4% compared to the same quarter last year. As a group, analysts expect that Kenvue Inc. will post 1.07 EPS for the current fiscal year.

Kenvue Dividend Announcement

The company also recently disclosed a quarterly dividend, which was paid on Wednesday, November 27th. Investors of record on Wednesday, November 13th were issued a dividend of $0.205 per share. The ex-dividend date was Wednesday, November 13th. This represents a $0.82 annualized dividend and a dividend yield of 3.69%. Kenvue’s dividend payout ratio is 149.09%.

Wall Street Analysts Forecast Growth

KVUE has been the topic of a number of research reports. Royal Bank of Canada upgraded shares of Kenvue from a “hold” rating to a “moderate buy” rating in a report on Monday, December 9th. Barclays raised Kenvue to a “hold” rating in a report on Thursday. Bank of America raised their price objective on Kenvue from $24.00 to $27.00 and gave the stock a “buy” rating in a research note on Tuesday, October 22nd. JPMorgan Chase & Co. lifted their target price on Kenvue from $24.00 to $25.00 and gave the stock an “overweight” rating in a report on Friday, October 11th. Finally, Piper Sandler upped their target price on Kenvue from $20.00 to $21.00 and gave the company a “neutral” rating in a report on Monday, September 23rd. One analyst has rated the stock with a sell rating, eight have assigned a hold rating and three have given a buy rating to the company’s stock. According to data from MarketBeat, the stock currently has an average rating of “Hold” and a consensus price target of $22.64.

About Kenvue

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.